Pharmasum Therapeutics AS is a private Norwegian specialty pharmaceutical company focused on the discovery and development of differentiated drugs for the treatment of autoimmune / metabolic and neurological diseases.

Founded in 2014 on the spin-out of industrial research on protein kinases, Pharmasum has offices in Tromsø and Oslo in Norway, and representation in the UK and USA. 

The company has an experienced management, board and international team of advisors.

About us | Management team

Anders Fugelli, PhD

Chief Executive Officer

Anders Fugelli is Co-founder of Pharmasum Therapeutics. He has a passion for brain diseases, with more than 20 years’ experience in academia and industrial R&D. He comes from a role as Head of Business Development in Norwegian start-up pharmaceuticals company Lytix Biopharma and has worked as Partner of life sciences and technology advisors, Amino AS. During the merger of GlaxoWellcome and SmithKlineBeecham, Anders was responsible, as Worldwide Assistant Director of Clinical Development and Product Strategy, of bringing together an overall company approach to the migraine field of the Neurology teams.

Anders received his BSc (hons) from Imperial College, London, and PhD in neuropharmacology from the University of London (Imperial College) for work carried out at the Insitut Pasteur, Paris and the Department of Preclinical Medical Sciences, Oslo. He also has additional training in corporate finance from the London Business School.

Anders Fugelli is a Norwegian citizen.

John Sigurd Svendsen, PhD

Chief Scientific Officer

John Sigurd Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry. He is a co-founder of the company and serves as its Chief Scientific Officer. Previously, he was Head of the exploratory research in Lytix Biopharma. John received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.

John Sigurd Svendsen is a Norwegian citizen.

Pauline Stewart-Long, PhD

Head of Project Management

Pauline Stewart-Long is a biochemist by training and started her career in the Pharmaceutical industry conducting clinical trials in several therapeutic areas, notably cardiovascular, metabolic and neuroscience.  She has more than 20 years’ broad experience in pharmaceutical R&D project & portfolio management, initially managing projects and then as a Portfolio Director she established portfolio and project management in the GSK Respiratory CEDD.  As VP in GSK Global Project Management, Pauline was accountable for the practices, processes and tools covering all stages of discovery and development and providing highly capable project managers to all therapy areas. She is currently Director of Stewart-Long Solutions Ltd and assisting a number of companies as an independent advisor to develop their project management capability appropriately alongside business growth.

Pauline Stewart-Long is a British citizen.

Henning Mork

Chief Financial Officer

Henning Mork has wide senior management experience from manufacturing industry, IT, consultancy business and biotech. His working experience includes finance, business development, sales management and business process improvement projects across several industries as well as general management. Henning has extensive experience in contract negotiations and deal making and has worked for large, listed companies, as well as start-ups. He is educated as a market economist with a diploma with additional studies in investment and finance from the Norwegian Business School (BI), and also has an undergraduate degree in political science from the University of Oslo.

Henning Mork is a Norwegian citizen.

About us | Board of directors

Andrew A Parsons, PhD

Chairman

Andrew Parsons is highly experienced in preclinical drug discovery and development with over 20 years’ experience leading units in the US and UK.  As a pharmacologist and neuroscientist, he was a founding member of the GSK Centre of Excellence for External Drug Discovery (CEEDD) and VP Preclinical Development in the Unit. Previously, he was Head Preclinical Discovery and an executive member of the Neurology and Gastrointestinal CEDD.  Prior to his development roles Andrew was Head of various research units including Migraine, Stroke, Neuropathic Pain and Neurodegeneration.  He has extensive experience in all stages of discovery and development.  Andrew was also the former Chairman of the Imigran Scientific Advisory Board. He is currently Director of Reciprocal Minds Limited and has interests in integrated healthcare models and open innovation.

Andrew Parsons is a British citizen.

Øystein Soug, MSc

Director

Øystein Soug is CEO of Targovax ASA, a listed Norwegian biotech company. He is the former CFO of Algeta ASA which was sold to Bayer AG for USD 2.9 billion in 2014. Prior to joining Algeta in 2008 Mr Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division. Mr Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development. He received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997.

Øystein Soug is a Norwegian citizen.

Mark Treherne, PhD

Director

Mark Treherne has over 25 years’ experience in drug discovery and development, having served on the boards of fifteen private and public companies and been Chief Executive for UK Trade and Investment in Biotechnology. He co -founded Cambridge Drug Discovery as Chief Executive in 1997, which he sold in 2001 to BioFocus plc, which was subsequently acquired by Galapagos. Mark also worked at Pfizer to lead its neurodegeneration research team in the UK, and has a BSc in Physiology from St Andrews University and a PhD in receptor neuropharmacology from the University of Cambridge. Chief Executive for UK Trade and Investment in Biotechnology.

Mark Treherne is a British citizen.

John Sigurd Svendsen, PhD

Chief Scientific Officer

John Sigurd Svendsen brings extensive research experience from work in medical biochemistry, synthetic organic chemistry and medicinal chemistry. He is a co-founder of the company and serves as its Chief Scientific Officer. Previously, he was Head of the exploratory research in Lytix Biopharma. John received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø.

John Sigurd Svendsen is a Norwegian citizen.

Team expertise
Martin Lunnon, PhD

Translational Medicine: Martin has more than 35 years’ experience in translational medicine. He has formerly worked for GSK and Sanofi and has lead projects of more than 30 NMEs into man.

Rod Porter, PhD

Development chemistry: Rod is an experienced medicinal chemist, and was formerly with GSK.

Allison Morgan, PhD

Regulatory/clinical: Allison is an experienced orphan disease specialist, and was formerly with Prosensa.

Jeffrey Sprouse, PhD

Pharmacology: Jeffrey has over 20 years’ pharma R&D experience. He led projects in circadian rhythm modulation at Pfizer and Lundbeck.

Nigel Toseland, PhD

Tox / Safety: Nigel has over 30 years’ experience in preclinical tox/safety at GSK.